Envoy Medical, Inc. (COCHW) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-17

Key Insights

Chas McKhann, a director of Envoy Medical, Inc., acquired 100,000 stock options exercisable at $0.72 per share. This suggests McKhann is bullish on the company's prospects.
The stock options will vest pro rata over a 3-year period starting May 15, 2026, indicating a long-term commitment from the director.
Insider buying of this magnitude, especially by a director, is typically viewed as a positive signal by investors about the company's future performance.

Want the newest filings?

This analysis covers the filing from 2026-04-17. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-02-17

The reporting person, Glen A. Taylor, has made a substantial purchase of 18,750,000 shares of Class A common stock in Envoy Medical, Inc. at $0.4 per share.
Taylor also holds indirect beneficial ownership of 2,526,058 shares through Taylor Sports Group and 4,810,384 shares through GAT Funding, LLC, indicating a significant stake in the company.
The company has granted the reporting person 11,250,000 Series A-1 warrants and 18,750,000 Series A-2 warrants, which are exercisable upon stockholder approval and tied to key milestones related to the company's Acclaim cochlear implant product.

Filed: 2026-02-17

Brent T. Lucas, the CEO of Envoy Medical, Inc., has acquired 62,500 shares of the company's Class A common stock at $0.40 per share, increasing his direct ownership to 297,090 shares.
Lucas also holds stock options and warrants that could potentially increase his beneficial ownership to 1,250,236 shares of Class A common stock.
The warrant acquisitions are subject to shareholder approval, indicating the company may be seeking to raise additional capital or expand its operations.

Filed: 2026-02-17

The reporting person, Charles Brynelsen, has purchased 1 million shares of Envoy Medical's Class A common stock at $0.4 per share, indicating insider confidence in the company.
Brynelsen also holds 62,500 stock options with an exercise price of $2.4, as well as 600,000 and 1,000,000 warrants with an exercise price of $0.4, further increasing his stake in the company.
The warrants are exercisable upon shareholder approval, with the Series A-1 warrants expiring two years from the initial exercise date or 30 days after the company submits a Premarket Approval Application to the FDA, and the Series A-2 warrants expiring five years from the initial exercise date or 30 days after the company receives FDA approval for its Acclaim CI Device.

Filed: 2026-02-17

The reporting person, Susan Kantor, acquired 96,150 shares of Envoy Medical, Inc. (COCHW) at $0.4 per share on 02/12/2026, increasing her direct beneficial ownership to 174,037 shares.
In addition to the share purchase, Kantor also holds 62,500 stock options with an exercise price of $2.4 and 62,500 stock options with an exercise price of $0.813, as well as 57,690 and 96,150 warrants with an exercise price of $0.4.
The warrant acquisitions are subject to shareholder approval and have various expiration dates tied to regulatory milestones for Envoy Medical's Acclaim CI Device.

Filed: 2026-02-17

Insider Robert Potashnick purchased 212,500 shares of Envoy Medical's Class A common stock at $0.40 per share, indicating his confidence in the company's prospects.
Potashnick also received 127,500 and 212,500 warrants to purchase additional Class A shares at $0.40 per share, suggesting he believes the stock is undervalued.
The options and warrants are subject to shareholder approval and vesting schedules, indicating Potashnick's long-term commitment to Envoy Medical.

Filed: 2026-02-17

Mona Chetan Patel, a director of Envoy Medical, Inc., acquired 312,500 shares of Class A common stock through the exercise of warrants at $0.4 per share, increasing her direct beneficial ownership to 332,500 shares.
The company granted Patel two additional stock options, one for 25,000 shares at an exercise price of $2.4 and another for 25,000 shares at an exercise price of $0.813, both with long-term vesting schedules.
The warrant exercises and stock option grants suggest Patel's confidence in the company's long-term prospects and alignment with shareholder interests.

Filed: 2026-02-09

Brent T. Lucas, the Chief Executive Officer of Envoy Medical, Inc., has engaged in a significant stock transaction, disposing of 234,590 shares of Class A Common Stock.
Lucas also holds stock options and warrants that provide him the right to acquire additional 1,089,736 shares of Class A Common Stock, suggesting he maintains a substantial equity stake in the company.
The company granted Lucas 200,000 additional stock options, which vest over a 3-year period, indicating his continued leadership role and the board's confidence in his management.

Filed: 2026-02-09

The reporting person, Robert Potashnick, acquired 15,000 stock options as the Interim CFO of Envoy Medical, Inc. This suggests insider confidence in the company's future performance.
The options have a 10-year term and vest over 3 years, indicating a long-term commitment from the Interim CFO.
The exercise price of $0.53 per share is below the current market price, potentially signaling the Interim CFO believes the stock is undervalued.

Other reports for Envoy Medical, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.